{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T08:02:41Z","timestamp":1784361761607,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Globally, pancreatic cancer is one of the leading causes of cancer-related mortality. Although FDA-approved chemotherapy regimens are available, rapid deterioration is often observed after first-line treatment. The PARP inhibitor niraparib may offer a therapeutic benefit in patients with advanced pancreatic cancer, necessitating thorough investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This was an open-label, single-arm, phase II trial involving 37 patients with metastatic or unresectable pancreatic cancer with DNA damage repair (DDR) gene alterations. Patients were administered niraparib (300 or 200\u2009mg daily, based on weight and platelet count) in 28-day cycles until disease progression, unacceptable toxicity, or withdrawal. Efficacy was assessed using the 6-month progression-free survival (PFS) rate as the primary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 37 patients, 29 were evaluated for efficacy. The 6-month PFS rate was 41.38% (12\/29 patients; 95% CI, 4.70%-100%), the median PFS was 4.4\u2009months (95% CI, 3.6-6.5\u2009months), and the median OS was 10.3\u2009months (95% CI, 7.6-15.9\u2009months). Further subgroup analysis revealed that the BRCA1\/2 germline mutation-positive patient group (n\u2009=\u200914) reported a 6-month PFS rate of 50% and a median overall survival (mOS) of 12.1\u2009months, while the non-BRCA group (n\u2009=\u200915) showed a 6-month PFS rate of 33.33% and a mOS of 10.3\u2009months. Adverse events occurred in 78% of patients, the most common being anemia (27%), and no treatment-related deaths were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data demonstrate clinical activity of niraparib in patients with metastatic or unresectable pancreatic cancers harboring DDR gene defects. Future studies are warranted to establish their roles in diverse genetic patient subpopulations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov identifier<\/jats:title>\n                    <jats:p>NCT03553004.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag225","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:42:06Z","timestamp":1780573326000},"source":"Crossref","is-referenced-by-count":0,"title":["Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): a phase II study (NIRA-PANC)"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4305-5701","authenticated-orcid":false,"given":"Anup","family":"Kasi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed Moh\u2019d Taiseer","family":"Al-Rajabi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquina Celebre","family":"Baranda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqiang","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhakar","family":"Chalise","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Data Science, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Weir","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Pharmacology and Therapeutics, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Sear","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Pharmacology and Therapeutics, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Carroll","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Bradbury","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5819-132X","authenticated-orcid":false,"given":"Alok","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hyter","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatadri","family":"Beeki","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"McKittrick","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Kumer","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Soper","sequence":"additional","affiliation":[{"name":"School of Biomedical Engineering, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K","family":"Godwin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Kansas Medical Center , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2026071803120965400_oyag225-B1","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/sim.3123","article-title":"Proper inference from Simon\u2019s two-stage designs","volume":"27","author":"Koyama","year":"2008","journal-title":"Stat Med"},{"key":"2026071803120965400_oyag225-B2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00280-017-3455-x","article-title":"Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients","volume":"81","author":"van Andel","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026071803120965400_oyag225-B3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/jjco\/hyab013","article-title":"The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study","volume":"51","author":"Yonemori","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2026071803120965400_oyag225-B4","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.clinthera.2024.06.001","article-title":"Niraparib population pharmacokinetics and exposure-response relationships in patients with newly diagnosed advanced ovarian cancer","volume":"46","author":"Monk","year":"2024","journal-title":"Clin Ther"},{"key":"2026071803120965400_oyag225-B5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.5114\/aoms.2020.94845","article-title":"The global burden of pancreatic cancer","volume":"16","author":"Lippi","year":"2020","journal-title":"Arch Med Sci"},{"key":"2026071803120965400_oyag225-B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026071803120965400_oyag225-B7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"2026071803120965400_oyag225-B8","doi-asserted-by":"publisher","first-page":"2129884","DOI":"10.1080\/08941939.2022.2129884","article-title":"Pancreatic cancer: a review of current treatment and novel therapies","volume":"36","author":"Kolbeinsson","year":"2023","journal-title":"J Invest Surg"},{"key":"2026071803120965400_oyag225-B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122700","article-title":"Optimal upfront treatment in surgically resectable pancreatic cancer candidates: a high-volume center retrospective analysis","volume":"10","author":"Maloney","year":"2021","journal-title":"J Clin Med"},{"key":"2026071803120965400_oyag225-B10","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"2026071803120965400_oyag225-B11","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"2026071803120965400_oyag225-B12","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1097\/CAD.0b013e328364e66b","article-title":"FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience","volume":"24","author":"Moretto","year":"2013","journal-title":"Anticancer Drugs"},{"key":"2026071803120965400_oyag225-B13","doi-asserted-by":"publisher","first-page":"4533","DOI":"10.3748\/wjg.v18.i33.4533","article-title":"FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts","volume":"18","author":"Neuzillet","year":"2012","journal-title":"World J Gastroenterol"},{"key":"2026071803120965400_oyag225-B14","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00280-012-1875-1","article-title":"FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study","volume":"69","author":"Zaniboni","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026071803120965400_oyag225-B15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"2026071803120965400_oyag225-B16","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41575-021-00463-z","article-title":"The pancreatic cancer genome revisited","volume":"18","author":"Hayashi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2026071803120965400_oyag225-B17","first-page":"409","article-title":"Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations","volume":"60","author":"Lal","year":"2000","journal-title":"Cancer Res"},{"key":"2026071803120965400_oyag225-B18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1126\/science.1171202","article-title":"Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene","volume":"324","author":"Jones","year":"2009","journal-title":"Science"},{"key":"2026071803120965400_oyag225-B19","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma","volume":"33","author":"Holter","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026071803120965400_oyag225-B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1615\/critreveukaryotgeneexpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"2026071803120965400_oyag225-B21","doi-asserted-by":"publisher","first-page":"Cd007929","DOI":"10.1002\/14651858.CD007929.pub4","article-title":"Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer","volume":"2","author":"Tattersall","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2026071803120965400_oyag225-B22","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"2026071803120965400_oyag225-B23","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2025.03.018","article-title":"Engot-OV16\/NOVA trial of niraparib in recurrent ovarian cancer: survival and long\u2011term safety","volume":"195","author":"Matulonis","year":"2025","journal-title":"Gynecol Oncol"},{"key":"2026071803120965400_oyag225-B24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026071803120965400_oyag225-B25","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/JCO.21.01604","article-title":"Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer","volume":"40","author":"Kindler","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026071803120965400_oyag225-B26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2017.11.004","article-title":"Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma","volume":"89","author":"Lowery","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026071803120965400_oyag225-B27","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00316","article-title":"Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation","volume":"2018","author":"Shroff","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2026071803120965400_oyag225-B28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"2026071803120965400_oyag225-B29","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1158\/2767-9764.CRC-22-0240","article-title":"Ad hoc analysis of the phase III ENGOT-OV16\/NOVA study: niraparib efficacy in germline BRCA wild-type recurrent ovarian cancer with homologous recombination repair defects","volume":"2","author":"Mirza","year":"2022","journal-title":"Cancer Res Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag225\/68483446\/oyag225.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag225\/68483446\/oyag225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag225\/68483446\/oyag225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T07:12:17Z","timestamp":1784358737000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag225\/8703245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag225","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,8]]},"article-number":"oyag225"}}